PhRMA, White House Spar Over Medicare Price Negotiation Messaging

A PhRMA study takes a narrow view of the beneficiary savings that Part D reforms in the Inflation Reduction Act could produce, sparking the Biden Administration to question its conclusions and the industry's motives.